[ad_1]
TORONTO, Sept. 9, 2022 /PRNewswire/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the HC Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022.
CEO Dr. Roger McIntyre will present virtually during the conference providing a update on its recently acquired US based telemedicine business, KetaMD, as well as its progress expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors. The on -demand session will be available at 7:00 am ET Monday September 12, 2022.
Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with HC Wainwright.
Braxia Scientific…
Full story available on Benzinga.com
[ad_2]
Source link
